Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
WT limb-blood syndrome is characterized by hematological anomalies (Fanconi anemia, leukemia and lymphoma) often appearing during childhood. Anomalies of the limbs and hands are also present: bifid or hypoplastic thumbs, cutaneous syndactyly, and ulnar and radial defects. The syndrome has been described in several families. Transmission is autosomal dominant.
Biomarker and diagnostic research for WT limb-blood syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for WT limb-blood syndrome.
159 publications have been identified in PubMed for WT limb-blood syndrome. Research spans Review / Meta-Analysis (45%), Basic Science / Preclinical (30%), and Case Report / Case Series (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 72 | 45% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about WT limb-blood syndrome
47 |
30% |
Patient case studies | 10 | 6% |
Clinical study results | 9 | 6% |
New treatment approaches | 9 | 6% |
Testing and diagnosis research | 6 | 4% |
Disease patterns and progression | 6 | 4% |
Kantarjian H (2026). [PMID: 41761287](https://pubmed.ncbi.nlm.nih.gov/41761287/). *American journal of hematology*. [Review / Meta-Analysis]
Huang F (2026). [PMID: 40590394](https://pubmed.ncbi.nlm.nih.gov/40590394/). *Cell Prolif*. [Basic Science / Preclinical]
McGuigan A (2026). [PMID: 41653248](https://pubmed.ncbi.nlm.nih.gov/41653248/). *Drugs*. [Review / Meta-Analysis]
Sadeghi MH (2026). [PMID: 40854259](https://pubmed.ncbi.nlm.nih.gov/40854259/). *Clinica chimica acta; international journal of clinical chemistry*. [Review / Meta-Analysis]
Doherty-Boyd WS (2026). [PMID: 41187596](https://pubmed.ncbi.nlm.nih.gov/41187596/). *Biomaterials*. [Gene Therapy / Novel Therapeutics]
Mahdavi L (2026). [PMID: 41027490](https://pubmed.ncbi.nlm.nih.gov/41027490/). *Exp Hematol*. [Basic Science / Preclinical]
Li F (2026). [PMID: 41806835](https://pubmed.ncbi.nlm.nih.gov/41806835/). *Cell*. [Clinical Trial Publication]
Klootsema Y (2026). [PMID: 41399259](https://pubmed.ncbi.nlm.nih.gov/41399259/). *Cell Cycle*. [Basic Science / Preclinical]
Duarte FB (2026). [PMID: 41628632](https://pubmed.ncbi.nlm.nih.gov/41628632/). *Lancet Haematol*. [Review / Meta-Analysis]
Cullen JM (2026). [PMID: 41532548](https://pubmed.ncbi.nlm.nih.gov/41532548/). *FEBS Lett*. [Review / Meta-Analysis]